DiaDexus' PLA2 Prostate Cancer Test Licensed By SB For Use As "Homebrew"
This article was originally published in The Gray Sheet
Executive SummarySmithKline Beecham Clinical Laboratories plans to develop and perform laboratory use-only PLA2 testing to measure the stages of development of prostate cancer under an exclusive agreement with molecular diagnostics firm DiaDexus announced Feb. 25.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.